Citation Impact
Citing Papers
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
2009
Coevolution of Prostate Cancer and Bone Stroma in Three-Dimensional Coculture: Implications for Cancer Growth and Metastasis
2008
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
2008 Standout
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Endocrine Disruptors and Asthma-Associated Chemicals in Consumer Products
2012 Standout
A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis
2007
Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense
2004
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution
2024 StandoutNobel
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
2006
Cancer treatment and survivorship statistics, 2022
2022 Standout
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
2008
Midwifery practice and the crisis of modernity: implications for the role of the midwife
2003 Standout
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
2009 Standout
Current and coming challenges in the management of the survivorship population
2020
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
<p>Antitumor activity of larotrectinib in tumors harboring <em>NTRK </em>gene fusions: a short review on the current evidence</p>
2019
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Complementary and alternative medicine: use and disclosure in radiation oncology community practice
2010 Standout
Natural products: A continuing source of novel drug leads
2013 Standout
Pancreatic cancer
2020 Standout
Dietary Supplement Use in Cancer Care: Help or Harm
2008
The biology and management of non-small cell lung cancer
2018 StandoutNature
The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
2007
Antiangiogenic effects of flavonoids and chalcones
2008
Cancer Statistics, 2006
2006 Standout
Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer
2004 Standout
Drug Interactions With Herbal Medicines
2007
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
2012
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
2020
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
2014 Standout
`Total pain', disciplinary power and the body in the work of Cicely Saunders, 1958–1967
1999 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Targeting multidrug resistance in cancer
2006 Standout
‘Giving midwifery care’: student midwives' views of their working role
2001
Targeting apoptosis in cancer therapy
2020 Standout
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules
2021
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Thalidomide
2004
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Cell cycle, CDKs and cancer: a changing paradigm
2009 Standout
Chemotherapy-induced peripheral neurotoxicity
2010
New aspects of natural products in drug discovery
2007
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Herb-Drug Interactions
2005 Standout
Ixabepilone for the treatment of breast cancer
2011
The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety
2014 Standout
NTRK fusion-positive cancers and TRK inhibitor therapy
2018
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs
2019
Chiral Toxicology: It's the Same Thing…Only Different
2009
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Aristolochic acid nephropathy: A worldwide problem
2008 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Potential medicinal plants for CNS disorders: an overview
2006
Plant Phenolics: Extraction, Analysis and Their Antioxidant and Anticancer Properties
2010 Standout
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Bisphosphonates for advanced prostate cancer
2006
Recent progress in the discovery and development of cyclin-dependent kinase inhibitors
2005
Management of glioblastoma: State of the art and future directions
2020 Standout
Microfluidics: Fluid physics at the nanoliter scale
2005 Standout
Measurement of the viscosity of liquids in very thin films
1986
Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
2012
Chemotherapy‐Induced Polyneuropathy: Major Agents and Assessment by Questionnaires
2014
Review of convective heat transfer enhancement with nanofluids
2009 Standout
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
2006
Plant Nitrogen Assimilation and Use Efficiency
2012 Standout
Traditional Chinese medicines
2004
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Asymmetric Synthesis of Both Mirror Images of 3′-Fluorothalidomide by Enantiodivergent Fluorination Using a Single, Cinchona Alkaloid
2010
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
2004
Characterizing nitrogen use efficiency in natural and agricultural ecosystems to improve the performance of cereal crops in low-input and organic agricultural systems
2008
Structure and dynamics of nanofluids: Theory and simulations to calculate viscosity
2000
Perioperative Herbal Supplement Use in Cancer Patients: Potential Implications and Recommendations for Presurgical Screening
2005
SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile
2018
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Force measurements with the atomic force microscope: Technique, interpretation and applications
2005 Standout
The interplay between doctors and nurses—a negotiated order perspective
1996 Standout
Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia
2007
Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin
2017
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
2018
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma
2011
Bisphosphonates for advanced prostate cancer
2017
The Anticancer, Antioxidant and Antimicrobial Properties of the Sesquiterpene β-Caryophyllene from the Essential Oil of Aquilaria crassna
2015 Standout
Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer
2007
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Wetting and spreading
2009 Standout
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
2010
Individual Care? Power and Subjectivity in Therapeutic Relationships
1992
Pretreatment Prostate-Specific Antigen (PSA) Velocity and Doubling Time Are Associated With Outcome but Neither Improves Prediction of Outcome Beyond Pretreatment PSA Alone in Patients Treated With Radical Prostatectomy
2009
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
2006
Important Flavonoids and Their Role as a Therapeutic Agent
2020 Standout
Works of Michael C. Cox being referenced
Readings in the sociology of nursing
1978
The use of thalidomide in androgen-independent prostate cancer
2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
2006
Emerging drugs to replace current leaders in first-line therapy for breast cancer
2006
Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
2006
Pharmacogenetic Associations ofCYP2C19Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide
2002
Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma
2005
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma
2019
Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion
2003
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
2004
An experimental test of frankel's law of film thickness
1962
Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma
2018
Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel
2006
Genetic Variation for Nitrogen Assimilation and Translocation in Wheat. III. Nitrogen Translocation in Relation to Grain Yield and Protein1
1986
Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101
2016
The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
2017
A RANDOMIZED, PHASE II TRIAL OF KETOCONAZOLE PLUS ALENDRONATE VERSUS KETOCONAZOLE ALONE IN PATIENTS WITH ANDROGEN INDEPENDENT PROSTATE CANCER AND BONE METASTASES
2005
Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
2019
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
2018
Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
2010
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
2018